Contact UsBiological Products
> Biopharmaceutical Industry Insight & News > Biological Products
| Product | RENFLEXIS? | Company | Samsung Bioepis |
|---|---|---|---|
| Classification | Biosimilar | Active Ingredient | Infliximab |
| Reference Product | Remicade | Approval Date | 2015 |
| Indication | [Korea] Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Psoriasis, Crohn's disease, Ulcerative colitis | ||
| Description |
Following an approval in Dec 2015 in Korea, it was approved in EU (May 2016). RENFLEXIS? is a monoclonal antibody(mAb) which inhibits turnor necrosis factor alpha, known to modulate immune responses.
* RENFLEXIS? is commerciallized in EU as FLIXABI?. |
||
Korea Biomedicine Industry Association(KoBIA)
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
COPYRIGHT BY KoBIA. ALL RIGHTS RESERVED.